DTT 304
Alternative Names: DTT-304Latest Information Update: 28 May 2022
At a glance
- Originator Lytix Biopharma
- Developer Lytix Biopharma; Oslo University Hospital
- Class Antineoplastics; Immunotherapies; Peptides
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Colorectal cancer; Liver metastases
Most Recent Events
- 28 May 2022 No recent reports of development identified for preclinical development in Colorectal-cancer in Norway (Intratumoural, Injection)
- 28 May 2022 No recent reports of development identified for preclinical development in Liver metastases in Norway (Intratumoural, Injection)
- 21 Apr 2018 Preclinical trials in Colorectal cancer in Norway (Intratumoural)